What is Lifesci Capital's Forecast for GPCR Q3 Earnings?

Key Points

• Lifesci Capital has forecasted Structure Therapeutics Inc. will report Q3 2025 earnings of ($0.35) per share, with the company expected to have a full-year loss of ($0.82) EPS.
• Several brokerages, including Guggenheim and Cantor Fitzgerald, have revised their price targets for Structure Therapeutics, indicating a strong consensus rating of "Buy" with an average price target of $75.71.
• Institutional investors hold a significant 91.78% stake in Structure Therapeutics, with hedge funds recently increasing their positions in the company.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Equities researchers at Lifesci Capital issued their Q3 2025 earnings estimates for Structure Therapeutics in a research report issued to clients and investors on Monday, September 8th. Lifesci Capital analyst P. Dolezal forecasts that the company will post earnings of ($0.35) per share for the quarter. Lifesci Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share. Lifesci Capital also issued estimates for Structure Therapeutics' Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.29) EPS.

A number of other equities analysts have also weighed in on the stock. Guggenheim dropped their price target on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Cantor Fitzgerald restated an "overweight" rating and set a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, June 23rd. HC Wainwright decreased their price target on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. Finally, JMP Securities decreased their price target on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company's stock. According to MarketBeat, Structure Therapeutics currently has an average rating of "Buy" and a consensus target price of $75.71.

Structure Therapeutics Trading Up 7.0%

NASDAQ GPCR traded up $1.41 during trading hours on Thursday, hitting $21.61. 306,372 shares of the company's stock traded hands, compared to its average volume of 900,346. The business's fifty day moving average price is $18.93 and its two-hundred day moving average price is $20.64. The firm has a market capitalization of $1.24 billion, a P/E ratio of -20.60 and a beta of -1.89. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $45.37.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08).

Institutional Trading of Structure Therapeutics

Institutional investors have recently modified their holdings of the company. State of Wyoming bought a new stake in shares of Structure Therapeutics in the 2nd quarter valued at about $28,000. GF Fund Management CO. LTD. bought a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $34,000. National Bank of Canada FI boosted its holdings in shares of Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after buying an additional 2,766 shares in the last quarter. Assetmark Inc. boosted its stake in Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company's stock worth $60,000 after purchasing an additional 820 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd boosted its stake in Structure Therapeutics by 310.7% in the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock worth $74,000 after purchasing an additional 3,213 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.